Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis

被引:1
|
作者
Yuste, C. [1 ,15 ]
Passerat, V. [2 ,3 ]
Calais, G. [3 ,4 ]
Schipman, B. [5 ]
Vaugier, L. [6 ]
Paumier, A. [1 ]
Huertas, A. [7 ]
Hemery, C. G. [8 ]
Debelleix, C. [9 ]
Chamois, J. [10 ]
Blanchard, N. [11 ]
Septans, AL. [12 ]
Pointreau, Y. [3 ,4 ,12 ,13 ,14 ]
机构
[1] Inst Cancerol Ouest, Angers, France
[2] Ctr Bayard, Villeurbanne, France
[3] Colib Club Oncologues Liberaux, Le Mans, France
[4] Oncol & Radiotherapie CORAD, Tours, France
[5] Inst Cancerol Bourgogne, Dijon, France
[6] Inst Cancerol Ouest, St Herblain, France
[7] Inst Radiotherapie Sud Oise, Creil, France
[8] Polyclin Courlancy, Reims, France
[9] Clin Bordeaux Tivoli Ducos, Bordeaux, France
[10] Private Hosp, Saint Gregoire, France
[11] Clin Dentellieres, Valenciennes, France
[12] Weprom, Angers, France
[13] Ctr Jean Bernard, Inst Interreg Cancerol ILC, Le Mans, France
[14] Ctr Cancerol Sarthe CCS, Le Mans, France
[15] Inst Cancerol Ouest, 15 Rue Andre Boquel, F-49055 Angers, France
关键词
Stereotactic body radiation therapy; Oligometastasis; Adrenal gland; Local control; Survival; Prognostic factors; OLIGOMETASTASES; CRITERIA;
D O I
10.1016/j.ctro.2023.100708
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The adrenal gland is a common site of metastasis with a rate of up to 27% in autopsy series. The incidence of these metastases is increasing due to greater use of Positron Emission Tomography scans and improved overall survival of patients with metastatic cancers. Stereotactic body radiation therapy (SBRT) is a non-invasive treatment option for metastasis. The aim of this study is to assess prognostic factors influencing local control, progression-free and overall survival in oligometastatic patients treated with SBRT for an adrenal metastasis. Methods: In this multicentric retrospective study, we included patients with adrenal metastases treated with SBRT between 2010 and 2021 in eleven french centers. All primary tumors were included. Results: A total of 110 patients treated for 121 adrenal lesions were included. Non-small-cell lung cancer was the predominant histologic type (55.4 %). Eighty-two percent of patients had at least 2 metastatic sites. The median Planning Target Volume was 70 cm3 with a median prescription dose of 40 Gray (Gy). The mean Biologically Effective Dose (BED) 10 dose was 74.2 Gy. Local control at 1 and 2 years was 85.9 % and 72.5 % respectively. The median overall survival and progression-free survival were 31.6 and 8.5 months respectively. Local control was significantly improved by systemic treatment one month before or after SBRT (p = 0.009) and by a BED10 greater than or equal to 50 Gy (p = 0.003). In multivariate analysis, oligometastatic presentation (p = 0.009) and a metachronous metastatic presentation (p = 0.008) were independent factors for progression-free survival. Tolerance was excellent, no grade 3 and 4 toxicities were described due to SBRT. Conclusion: Stereotactic radiotherapy of adrenal metastases makes possible a local control of more than 85% at one year and was well tolerated. The factors influencing survival in oligometastatic patients still need to be found in order to better select those who benefit the most from this type of treatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
    Toesca, Diego A. S.
    Koong, Amanda J.
    von Eyben, Rie
    Koong, Albert C.
    Chang, Daniel T.
    ADVANCES IN RADIATION ONCOLOGY, 2018, 3 (04) : 621 - 629
  • [12] Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
    Scouarnec, Cyrielle
    Pasquier, David
    Luu, Joel
    le Tinier, Florence
    Lebellec, Laic
    Rault, Erwann
    Lartigau, Eric
    Mirabel, Xavier
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [13] Outcomes and Toxicities in Oligometastatic Patients Treated With Stereotactic Body Radiotherapy for Adrenal Gland Metastases: A Multi-Institutional Study
    Baydoun, A.
    Chen, H.
    Poon, I.
    Badellino, S.
    Dagan, R.
    Erler, D.
    Foote, M. C.
    Louie, A. V.
    Redmond, K. J.
    Ricardi, U.
    Sahgal, A.
    Biswas, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E474 - E474
  • [14] Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
    Rusthoven, Kyle E.
    Kavanagh, Brian D.
    Burri, Stuart H.
    Chen, Changhu
    Cardenes, Higinia
    Chidel, Mark A.
    Pugh, Thomas J.
    Kane, Madeleine
    Gaspar, Laurie E.
    Schefter, Tracey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1579 - 1584
  • [15] Japanese Multi-Institutional Study of Stereotactic Body Radiation Therapy for 380 Patients With Lung Metastases
    Onishi, H.
    Matsumoto, Y.
    Miyakawa, A.
    Yamashita, H.
    Nomiya, T.
    Niibe, Y.
    Nakata, K.
    Kuriyama, K.
    Komiyama, T.
    Marino, K.
    Aoki, S.
    Maehata, Y.
    Araya, M.
    Saito, R.
    Tomoinaga, L.
    Oguri, M.
    Watanabe, I.
    Nonaka, H.
    Sano, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S28 - S28
  • [16] Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
    Rusthoven, Kyle E.
    Kavanagh, Brian D.
    Cardenes, Higinia
    Stieber, Volker W.
    Burri, Stuart H.
    Feigenberg, Steven J.
    Chidel, Mark A.
    Pugh, Thomas J.
    Franklin, Wilbur
    Kane, Madeleine
    Gaspar, Laurie E.
    Schefter, Tracey E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1572 - 1578
  • [17] Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis
    Hashmi, Ahmed
    Guckenberger, Matthias
    Kersh, Ron
    Gerszten, Peter C.
    Mantel, Frederick
    Grills, Inga S.
    Flickinger, John C.
    Shin, John H.
    Fahim, Daniel K.
    Winey, Brian
    Oh, Kevin
    Cho, B. C. John
    Letourneau, Daniel
    Sheehan, Jason
    Sahgal, Arjun
    JOURNAL OF NEUROSURGERY-SPINE, 2016, 25 (05) : 646 - 653
  • [18] Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study
    Baydoun, A.
    Chen, H.
    Poon, I
    Badellino, S.
    Dagan, R.
    Erler, D.
    Foote, M. C.
    Louie, A., V
    Redmond, K. J.
    Ricardi, U.
    Sahgal, A.
    Biswas, T.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 33 : 159 - 164
  • [19] Stereotactic Body Radiation Therapy to Multiple Sites of Intrathoracic Disease: A Multi-Institutional Analysis
    Goodman, C. R.
    Zainib, M.
    Arshad, M.
    Cutright, D.
    Beydoun, H.
    Dominello, M. M.
    Mohindra, P.
    Amin, N. P.
    Simone, C. B., II
    Kruser, T. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E683 - E683
  • [20] Japanese Multi-institutional Study of Stereotactic Body Radiation Therapy for Totally 380 Patients With Lung Metastases
    Onishi, H.
    Matsumoto, Y.
    Miyakawa, A.
    Yamashita, H.
    Nomiya, T.
    Niibe, Y.
    Nakata, K.
    Kuriyama, K.
    Komiyama, T.
    Marino, K.
    Aoki, S.
    Maehata, Y.
    Araya, M.
    Saito, R.
    Tomoinaga, L.
    Oguri, M.
    Watanabe, I.
    Nonaka, H.
    Sano, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S46 - S47